A new treatment using CAR-T cells for chronic HIV infection
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed
This study is testing a new one-time treatment using your own immune cells to help people with HIV who struggle with regular medication, aiming to clear the virus from hidden spots in the body and keep it away for a long time.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Marpam Pharma, LLC NIH-funded |
| Lab location | 1 site (St. Paul, UNITED STATES) |
| Project ID | NIH-11032898 on NIH RePORTER |
What this research studies
This research focuses on developing a one-time CAR-T cell therapy aimed at achieving durable remission of HIV in patients who are not effectively treated with standard antiretroviral therapy (ART). The therapy utilizes the patient's own T cells, modified to target and eliminate HIV-infected cells hidden in specific areas of the immune system. By employing a specialized receptor, the modified T cells are directed to these 'hidden' viral reservoirs, potentially leading to a more effective treatment for chronic HIV infection. This approach is particularly relevant for individuals who are ART naïve or have difficulty adhering to ART regimens.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with chronic HIV infection who are not suppressed by ART, including those who are ART naïve or non-compliant.
Not a fit: Patients who are already effectively managed on ART or those with acute HIV infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a long-lasting solution for individuals living with chronic HIV infection, potentially eliminating the need for ongoing ART.
How similar studies have performed: While CAR-T cell therapies have shown promise in other areas, this specific application for chronic HIV infection is novel and has not been extensively tested in clinical settings.
Where this research is happening
St. Paul, UNITED STATES
- Marpam Pharma, LLC — St. Paul, United States (Active)
Researchers
- Principal investigator: Athanasiou, Maria Constance — Marpam Pharma, LLC
- Study coordinator: Athanasiou, Maria Constance
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.